JP2022505604A5 - - Google Patents
Info
- Publication number
- JP2022505604A5 JP2022505604A5 JP2021522004A JP2021522004A JP2022505604A5 JP 2022505604 A5 JP2022505604 A5 JP 2022505604A5 JP 2021522004 A JP2021522004 A JP 2021522004A JP 2021522004 A JP2021522004 A JP 2021522004A JP 2022505604 A5 JP2022505604 A5 JP 2022505604A5
- Authority
- JP
- Japan
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024019151A JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗ｎｐｒ１抗体およびその使用 |
| JP2025116272A JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗ｎｐｒ１抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749557P | 2018-10-23 | 2018-10-23 | |
| US62/749,557 | 2018-10-23 | ||
| US201862755720P | 2018-11-05 | 2018-11-05 | |
| US62/755,720 | 2018-11-05 | ||
| PCT/US2019/057033 WO2020086406A2 (en) | 2018-10-23 | 2019-10-18 | Anti-npr1 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019151A Division JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗ｎｐｒ１抗体およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022505604A JP2022505604A (ja) | 2022-01-14 |
| JP2022505604A5 true JP2022505604A5 (https=) | 2022-10-24 |
| JPWO2020086406A5 JPWO2020086406A5 (https=) | 2022-10-24 |
| JP7439076B2 JP7439076B2 (ja) | 2024-02-27 |
Family
ID=68732036
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522004A Active JP7439076B2 (ja) | 2018-10-23 | 2019-10-18 | 抗ｎｐｒ１抗体およびその使用 |
| JP2024019151A Active JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗ｎｐｒ１抗体およびその使用 |
| JP2025116272A Pending JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗ｎｐｒ１抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019151A Active JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗ｎｐｒ１抗体およびその使用 |
| JP2025116272A Pending JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗ｎｐｒ１抗体およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US11306148B2 (https=) |
| EP (1) | EP3870612A2 (https=) |
| JP (3) | JP7439076B2 (https=) |
| KR (1) | KR20210082207A (https=) |
| CN (1) | CN112805303B (https=) |
| AU (1) | AU2019368196B2 (https=) |
| CA (1) | CA3115102A1 (https=) |
| CL (3) | CL2021000942A1 (https=) |
| CO (1) | CO2021006663A2 (https=) |
| IL (1) | IL281297B1 (https=) |
| MX (2) | MX2021004284A (https=) |
| MY (1) | MY205168A (https=) |
| PH (1) | PH12021550255A1 (https=) |
| SG (1) | SG11202101037QA (https=) |
| WO (1) | WO2020086406A2 (https=) |
| ZA (1) | ZA202100714B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY205168A (en) | 2018-10-23 | 2024-10-04 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof |
| EA202193345A1 (ru) | 2019-06-12 | 2022-03-16 | Новартис Аг | Антитела к рецептору-1 натрийуретического пептида и способы их применения |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| US12281161B2 (en) | 2021-07-28 | 2025-04-22 | Trustees Of Boston University | Polypeptides and uses thereof |
| IL311917A (en) | 2021-10-11 | 2024-06-01 | Regeneron Pharma | Methods for Inducing Hemodynamic Change by Administering an Anti-NPR1 Antibody |
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
| WO2023187657A1 (en) | 2022-03-30 | 2023-10-05 | Novartis Ag | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies |
| WO2024251255A1 (zh) | 2023-06-08 | 2024-12-12 | 江苏恒瑞医药股份有限公司 | 抗npr1抗体及其医药用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| EP2162464A1 (en) * | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
| US9090695B2 (en) * | 2008-12-03 | 2015-07-28 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| CN102482715A (zh) | 2009-07-13 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | 用于癌症治疗的诊断方法和组合物 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| US9451770B2 (en) | 2012-06-08 | 2016-09-27 | Charles Despres | Method of activating immune response in plants |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| WO2016131943A1 (en) | 2015-02-20 | 2016-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes |
| WO2017209553A2 (ko) | 2016-06-03 | 2017-12-07 | 사회복지법인 삼성생명공익재단 | 환자 유래 세포를 이용한 항체 스크리닝 방법 |
| US20190248888A1 (en) * | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| US20190135804A1 (en) | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| MY205168A (en) | 2018-10-23 | 2024-10-04 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof |
| EP3898700A1 (en) | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| EA202193345A1 (ru) | 2019-06-12 | 2022-03-16 | Новартис Аг | Антитела к рецептору-1 натрийуретического пептида и способы их применения |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
-
2019
- 2019-10-18 MY MYPI2021001138A patent/MY205168A/en unknown
- 2019-10-18 JP JP2021522004A patent/JP7439076B2/ja active Active
- 2019-10-18 WO PCT/US2019/057033 patent/WO2020086406A2/en not_active Ceased
- 2019-10-18 US US16/657,000 patent/US11306148B2/en active Active
- 2019-10-18 MX MX2021004284A patent/MX2021004284A/es unknown
- 2019-10-18 CA CA3115102A patent/CA3115102A1/en active Pending
- 2019-10-18 KR KR1020217015469A patent/KR20210082207A/ko active Pending
- 2019-10-18 EP EP19812875.3A patent/EP3870612A2/en active Pending
- 2019-10-18 SG SG11202101037QA patent/SG11202101037QA/en unknown
- 2019-10-18 AU AU2019368196A patent/AU2019368196B2/en active Active
- 2019-10-18 CN CN201980065187.4A patent/CN112805303B/zh active Active
-
2021
- 2021-02-02 ZA ZA2021/00714A patent/ZA202100714B/en unknown
- 2021-02-03 PH PH12021550255A patent/PH12021550255A1/en unknown
- 2021-03-07 IL IL281297A patent/IL281297B1/en unknown
- 2021-04-14 MX MX2024011444A patent/MX2024011444A/es unknown
- 2021-04-15 CL CL2021000942A patent/CL2021000942A1/es unknown
- 2021-05-21 CO CONC2021/0006663A patent/CO2021006663A2/es unknown
-
2022
- 2022-03-10 US US17/692,084 patent/US11820826B2/en active Active
-
2023
- 2023-05-12 CL CL2023001377A patent/CL2023001377A1/es unknown
- 2023-10-11 US US18/485,241 patent/US20240059780A1/en not_active Abandoned
-
2024
- 2024-02-07 CL CL2024000378A patent/CL2024000378A1/es unknown
- 2024-02-13 JP JP2024019151A patent/JP7713051B2/ja active Active
- 2024-05-31 US US18/680,910 patent/US20240309103A1/en active Pending
-
2025
- 2025-07-10 JP JP2025116272A patent/JP2025148445A/ja active Pending